Anti-CD38 human antibodies and uses thereof

  • US 8,263,746 B2
  • Filed: 02/07/2005
  • Issued: 09/11/2012
  • Est. Priority Date: 02/06/2004
  • Status: Active Grant
First Claim
Patent Images

1. An isolated human antibody that specifically binds an epitope of CD38 (SEQ ID NO:

  • 22),wherein said antibody mediates killing of a CD38+ target cell by antibody dependent cellular cytotoxicity with at least five-fold better efficacy than chimeric OKT10 antibody (SEQ ID NOS;

    23 and

         24) under the same or substantially the same conditions when a human PBMC cell is employed as the effector cell,wherein said CD38+ target cell is selected from the group consisting of LP-1 (DSMZ;

    ACC41) and RPMI-8226 (ATCC;

    CCL-155), andwherein the ratio of effector cells to target cells is between about 30;

    1 and about 50;


View all claims

    Thank you for your feedback